J&J agrees to buy Mentor for $1.07B

8 December 2008

US health care major Johnson & Johnson has agreed to acquire cosmetic-product and breast-implant maker Mentor for $1.07 billion.

Mentor is expected to operate as a stand-alone business unit reporting through J&J unit Ethicon, a leading provider of suture, mesh and other products for a wide range of surgical procedures.

Under the terms of the deal, J&J will commence a tender offer to purchase all outstanding shares of Mentor at $31.00 each. The offer is conditioned on the tender of a majority of the outstanding shares of Mentor's common stock on a fully-diluted basis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight